
    
      Participants with stage IA-IIIA, surgically resectable lung adenocarcinoma with an activating
      alteration in ALK, ROS1 or MET will receive neoadjuvant treatment with crizotinib. This
      neoadjuvant treatment will last 6 weeks and on the last day of dosing of crizotinib,
      participants will undergo surgical resection, followed by 5 years of follow-up via chart
      review.
    
  